Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Sep;81(1):80–86. doi: 10.1038/sj.bjc.6690654

The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer

M D Barber 1, J A Ross 1, A C Voss 2, M J Tisdale 3, K C H Fearon 1
PMCID: PMC2374349  PMID: 10487616

Abstract

Previous studies have suggested that administration of oral eicosapentaenoic acid (EPA) will stabilize weight in patients with advanced pancreatic cancer. The aim of the present study was to determine if a combination of EPA with a conventional oral nutritional supplement could produce weight gain in these patients. Twenty patients with unresectable pancreatic adenocarcinoma were asked to consume two cans of a fish oil-enriched nutritional supplement per day in addition to their normal food intake. Each can contained 310 kcal, 16.1 g protein and 1.09 g EPA. Patients were assessed for weight, body composition, dietary intake, resting energy expenditure (REE) and performance status. Patients consumed a median of 1.9 cans day−1. All patients were losing weight at baseline at a median rate of 2.9 kg month−1. After administration of the fish oil-enriched supplement, patients had significant weight-gain at both 3 (median 1 kg, P = 0.024) and 7 weeks (median 2 kg, P = 0.033). Dietary intake increased significantly by almost 400 kcal day−1 (P = 0.002). REE per kg body weight and per kg lean body mass fell significantly. Performance status and appetite were significantly improved at 3 weeks. In contrast to previous studies of oral conventional nutritional supplements in weight-losing cancer patients, this study suggests that an EPA-enriched supplement may reverse cachexia in advanced pancreatic cancer. © 1999 Cancer Research Campaign

Keywords: pancreatic cancer, cachexia, eicosapentaenoic acid, docosahexaenoic acid, fish oil, nutritional supplementation

Full Text

The Full Text of this article is available as a PDF (104.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahlgren J. D. Epidemiology and risk factors in pancreatic cancer. Semin Oncol. 1996 Apr;23(2):241–250. [PubMed] [Google Scholar]
  2. Beck S. A., Smith K. L., Tisdale M. J. Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res. 1991 Nov 15;51(22):6089–6093. [PubMed] [Google Scholar]
  3. Cohn S. H., Vartsky D., Vaswani A. N., Sawitsky A., Rai K., Gartenhaus W., Yasumura S., Ellis K. J. Changes in body composition of cancer patients following combined nutritional support. Nutr Cancer. 1982;4(2):107–119. doi: 10.1080/01635588209513746. [DOI] [PubMed] [Google Scholar]
  4. Dewys W. D., Begg C., Lavin P. T., Band P. R., Bennett J. M., Bertino J. R., Cohen M. H., Douglass H. O., Jr, Engstrom P. F., Ezdinli E. Z. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980 Oct;69(4):491–497. doi: 10.1016/s0149-2918(05)80001-3. [DOI] [PubMed] [Google Scholar]
  5. Evans W. K., Nixon D. W., Daly J. M., Ellenberg S. S., Gardner L., Wolfe E., Shepherd F. A., Feld R., Gralla R., Fine S. A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol. 1987 Jan;5(1):113–124. doi: 10.1200/JCO.1987.5.1.113. [DOI] [PubMed] [Google Scholar]
  6. Falconer J. S., Fearon K. C., Plester C. E., Ross J. A., Carter D. C. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg. 1994 Apr;219(4):325–331. doi: 10.1097/00000658-199404000-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Falconer J. S., Fearon K. C., Ross J. A., Elton R., Wigmore S. J., Garden O. J., Carter D. C. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer. 1995 Apr 15;75(8):2077–2082. doi: 10.1002/1097-0142(19950415)75:8<2077::aid-cncr2820750808>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  8. Falconer J. S., Ross J. A., Fearon K. C., Hawkins R. A., O'Riordain M. G., Carter D. C. Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines. Br J Cancer. 1994 May;69(5):826–832. doi: 10.1038/bjc.1994.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fearon K. C., Falconer J. S., Ross J. A., Carter D. C., Hunter J. O., Reynolds P. D., Tuffnell Q. An open-label phase I/II dose escalation study of the treatment of pancreatic cancer using lithium gammalinolenate. Anticancer Res. 1996 Mar-Apr;16(2):867–874. [PubMed] [Google Scholar]
  10. Gogos C. A., Ginopoulos P., Salsa B., Apostolidou E., Zoumbos N. C., Kalfarentzos F. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. Cancer. 1998 Jan 15;82(2):395–402. doi: 10.1002/(sici)1097-0142(19980115)82:2<403::aid-cncr21>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  11. Hannan W. J., Cowen S. J., Plester C. E., Fearon K. C., deBeau A. Comparison of bio-impedance spectroscopy and multi-frequency bio-impedance analysis for the assessment of extracellular and total body water in surgical patients. Clin Sci (Lond) 1995 Dec;89(6):651–658. doi: 10.1042/cs0890651. [DOI] [PubMed] [Google Scholar]
  12. Heinrich P. C., Castell J. V., Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990 Feb 1;265(3):621–636. doi: 10.1042/bj2650621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lai P. B., Ross J. A., Fearon K. C., Anderson J. D., Carter D. C. Cell cycle arrest and induction of apoptosis in pancreatic cancer cells exposed to eicosapentaenoic acid in vitro. Br J Cancer. 1996 Nov;74(9):1375–1383. doi: 10.1038/bjc.1996.552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Leaf A., Weber P. C. Cardiovascular effects of n-3 fatty acids. N Engl J Med. 1988 Mar 3;318(9):549–557. doi: 10.1056/NEJM198803033180905. [DOI] [PubMed] [Google Scholar]
  15. McMillan D. C., O'Gorman P., Fearon K. C., McArdle C. S. A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br J Cancer. 1997;76(6):788–790. doi: 10.1038/bjc.1997.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Meydani S. N., Lichtenstein A. H., Cornwall S., Meydani M., Goldin B. R., Rasmussen H., Dinarello C. A., Schaefer E. J. Immunologic effects of national cholesterol education panel step-2 diets with and without fish-derived N-3 fatty acid enrichment. J Clin Invest. 1993 Jul;92(1):105–113. doi: 10.1172/JCI116537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Moldawer L. L., Copeland E. M., 3rd Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options. Cancer. 1997 May 1;79(9):1828–1839. [PubMed] [Google Scholar]
  18. Ovesen L., Allingstrup L., Hannibal J., Mortensen E. L., Hansen O. P. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol. 1993 Oct;11(10):2043–2049. doi: 10.1200/JCO.1993.11.10.2043. [DOI] [PubMed] [Google Scholar]
  19. Ovesen L., Hannibal J., Mortensen E. L. The interrelationship of weight loss, dietary intake, and quality of life in ambulatory patients with cancer of the lung, breast, and ovary. Nutr Cancer. 1993;19(2):159–167. doi: 10.1080/01635589309514246. [DOI] [PubMed] [Google Scholar]
  20. Perez M. M., Newcomer A. D., Moertel C. G., Go V. L., Dimagno E. P. Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer. Cancer. 1983 Jul 15;52(2):346–352. doi: 10.1002/1097-0142(19830715)52:2<346::aid-cncr2820520228>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  21. Simons J. P., Aaronson N. K., Vansteenkiste J. F., ten Velde G. P., Muller M. J., Drenth B. M., Erdkamp F. L., Cobben E. G., Schoon E. J., Smeets J. B. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. J Clin Oncol. 1996 Apr;14(4):1077–1084. doi: 10.1200/JCO.1996.14.4.1077. [DOI] [PubMed] [Google Scholar]
  22. Todorov P., Cariuk P., McDevitt T., Coles B., Fearon K., Tisdale M. Characterization of a cancer cachectic factor. Nature. 1996 Feb 22;379(6567):739–742. doi: 10.1038/379739a0. [DOI] [PubMed] [Google Scholar]
  23. Wigmore S. J., Fearon K. C., Maingay J. P., Ross J. A. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci (Lond) 1997 Feb;92(2):215–221. doi: 10.1042/cs0920215. [DOI] [PubMed] [Google Scholar]
  24. Wigmore S. J., Plester C. E., Richardson R. A., Fearon K. C. Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer. 1997;75(1):106–109. doi: 10.1038/bjc.1997.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Wigmore S. J., Plester C. E., Ross J. A., Fearon K. C. Contribution of anorexia and hypermetabolism to weight loss in anicteric patients with pancreatic cancer. Br J Surg. 1997 Feb;84(2):196–197. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES